RBC Capital lowered the firm’s price target on Inovio (INO) to $5 from $6 and keeps a Sector Perform rating on the shares. The company ...

Inovio Pharmaceuticals (NASDAQ:INO – Free Report) had its target price lowered by Royal Bank of Canada from $6.00 to $5.00 in a research report sent to investors on Wednesday,Benzinga reports. The ...

In a report released yesterday, Gregory Renza from RBC Capital maintained a Hold rating on Inovio Pharmaceuticals (INO – Research Report), with ...

Q4 2024 Management View CEO Jacqui Shea highlighted that Inovio remains committed to transforming into a commercial-stage company, with a primary focus on advancing INO-3107, a DNA medicine for ...

Inovio Pharmaceuticals Inc (INO) addresses manufacturing issues and progresses towards BLA submission, despite financial ...

Inovio Pharmaceuticals Inc. closed 86.91% short of its 52-week high of $14.75, which the company reached on April 1st.

INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today ...

Inovio Pharmaceuticals Inc. closed 86.10% short of its 52-week high of $14.75, which the company achieved on April 1st.